Important (bad) news came out yesterday with Celgene (CELG) down ~7% after-hours because of large Bristol-Myers (BMY) shareholder Wellington coming in and opposing the deal. I already flagged Wellington as the most important/likely shareholder to oppose the deal. Here's their rationale:
While Wellington agrees that Bristol-Myers should be active in business development that secures differentiated science and broadens the future revenue base, Wellington does not believe that the Celgene transaction is an attractive path towards accomplishing this goal. Wellington's conclusion is based upon three tenets: 1) the transaction asks BMY